{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:50:00Z","timestamp":1768081800093,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaesthesia Critical Care & Pain Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.accpm.2021.100963","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T09:40:02Z","timestamp":1634636402000},"page":"100963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["GFHT proposals on the practical use of argatroban \u2014 With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT)"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-8964","authenticated-orcid":false,"given":"Virginie","family":"Siguret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-6375","authenticated-orcid":false,"given":"Elodie","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-2701","authenticated-orcid":false,"given":"Chlo\u00e9","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Godon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Ajzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"B\u00e9jot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Crassard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouhadjar","family":"Dahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Desconclois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Flaujac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Fr\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Godier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"H\u00e9zard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Jourdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charl\u00e8ne","family":"Kuadjovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Laurichesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"M\u00e9mier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Toussaint-Hacquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.accpm.2021.100963_bib0005","unstructured":"Argatroban \u2013 Summary of Product Characteristics. European Medicines Agency, September 14, 2021."},{"key":"10.1016\/j.accpm.2021.100963_bib0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MOH.0000000000000273","article-title":"Management of heparin-induced thrombocytopaenia","volume":"23","author":"Warkentin","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0015","first-page":"291","article-title":"Members of the French Working Group on Perioperative Haemostasis Groupe d\u2019int\u00e9r\u00eat en h\u00e9mostase p\u00e9riop\u00e9ratoire GIHP. Diagnosis and management of heparin-induced thrombocytopaenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11096-021-01260-z","article-title":"Superior outcomes with argatroban for heparin-induced thrombocytopaenia: a Bayesian network meta-analysis","volume":"43","author":"Colarossi","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.accpm.2021.100963_bib0025","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise Neuro-vasculaire, Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Vasculaire, Groupe Fran\u00e7ais d\u2019\u00e9tudes sur l\u2019H\u00e9mostase et la Thrombose. Prise en charge des SARS-CoV-2 Vaccine Induced Thrombotic Thrombocytopaenia - April 27, 2021. https:\/\/site.geht.org\/docutheque\/."},{"key":"10.1016\/j.accpm.2021.100963_bib0030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopaenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0035","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopaenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0045","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopaenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced thrombotic thrombocytopaenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0055","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1097\/CCM.0000000000005105","article-title":"Using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccination-related vaccine-induced immune thrombotic thrombocytopaenia","volume":"49","author":"Bersinger","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2021.100963_bib0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopaenia after COVID-19 vaccine","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2021.100963_bib0065","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(21)01238-1","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopaenia treated with immunoglobulin and argatroban","volume":"397","author":"Guetl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2021.100963_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17619","article-title":"Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopaenia (VITT)","author":"Ramdeny","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0075","first-page":"1","author":"Graf","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.accpm.2021.100963_bib0080","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1161\/STROKEAHA.121.035613","article-title":"Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopaenia","volume":"52","author":"Siegler","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.accpm.2021.100963_bib0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjmed.2008.03.012","article-title":"A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopaenia","volume":"121","author":"Warkentin","year":"2008","journal-title":"Am J Med"},{"issue":"June","key":"10.1016\/j.accpm.2021.100963_bib0090","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopaenia (VITT) for SARS-CoV-2 infections: communication from the ISTH SSC Subcommittee on Platelet Immunology","author":"Nazy","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0095","author":"Pavord"},{"key":"10.1016\/j.accpm.2021.100963_bib0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH","volume":"41","author":"Oldenburg","year":"2021","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.accpm.2021.100963_bib0105","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopaenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0110","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/jth.15344","article-title":"GFHT-HIT study group. Heparin-induced thrombocytopaenia: construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation","volume":"19","author":"Tardy-Poncet","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0115","article-title":"Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopaenia in Switzerland","volume":"150","author":"Alberio","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.accpm.2021.100963_bib0120","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2021.100963_bib0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.accpm.2021.100963_bib0130","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1160\/TH15-11-0847","article-title":"Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopaenia","volume":"115","author":"Keyl","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.thromres.2011.11.041","article-title":"Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopaenia requiring antithrombotic therapy \u2014 a European Perspective","volume":"129","author":"Alatri","year":"2012","journal-title":"Thromb Res"},{"issue":"2 Suppl","key":"10.1016\/j.accpm.2021.100963_bib0140","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopaenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2021.100963_bib0145","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13054-015-1109-0","article-title":"Argatroban in the management of heparin-induced thrombocytopaenia: a multicenter clinical trial","volume":"19","author":"Tardy-Poncet","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2021.100963_bib0150","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ene.13381","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis \u2014 endorsed by the European Academy of Neurology","volume":"24","author":"Ferro","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.accpm.2021.100963_bib0155","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","article-title":"A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease","volume":"66","author":"Murray","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.accpm.2021.100963_bib0160","series-title":"Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline \u2013 fifth Edition. CLSI Document H21-A5","author":"CLSI","year":"2008"},{"key":"10.1016\/j.accpm.2021.100963_bib0165","unstructured":"Groupe Fran\u00e7ais d\u2019\u00e9tudes sur l\u2019H\u00e9mostase et la Thrombose. Recommandations pr\u00e9-analytiques en h\u00e9mostase, https:\/\/site.geht.org\/docutheque\/ Accessed July 31, 2021."},{"key":"10.1016\/j.accpm.2021.100963_bib0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.mbc.0000169217.15926.d0","article-title":"Effect of argatroban on the activated partial thromboplastin time: comparison of 21 commercial reagents","volume":"16","author":"Francis","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.accpm.2021.100963_bib0175","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/ijlh.12414","article-title":"Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban","volume":"37","author":"Guy","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0180","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjh.14397","article-title":"Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor argatroban","volume":"180","author":"Guy","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0185","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1R745","article-title":"Apparent argatroban resistance in a patient with elevated factor VIII levels","volume":"47","author":"Kennedy","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.accpm.2021.100963_bib0190","doi-asserted-by":"crossref","first-page":"E303","DOI":"10.1002\/ajh.24344","article-title":"Argatroban monitoring: aPTT versus chromogenic assay","volume":"91","author":"Vu","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0036-1597297","article-title":"Laboratory monitoring of parenteral direct thrombin inhibitors","volume":"43","author":"Van Cott","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ajh.25852","article-title":"Ecarin based coagulation testing","volume":"95","author":"Gosselin","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0205","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ijlh.12844","article-title":"Argatroban is stable in citrated whole blood for 24 hours","volume":"40","author":"Guy","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.accpm.2021.100963_bib0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1076029617699087","article-title":"Monitoring of argatroban and lepirudin: what is the input of laboratory values in \u201creal life\u201d?","volume":"24","author":"Seidel","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0215","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH05-03-0154","article-title":"Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation","volume":"94","author":"Warkentin","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2021.100963_bib0220","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ijlh.12719","article-title":"Influences of argatroban on five fibrinogen assays","volume":"39","author":"Zhang","year":"2017","journal-title":"Int J Lab Hematol"}],"container-title":["Anaesthesia Critical Care & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556821001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556821001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:49:50Z","timestamp":1762480190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352556821001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2352556821001673"],"URL":"https:\/\/doi.org\/10.1016\/j.accpm.2021.100963","relation":{},"ISSN":["2352-5568"],"issn-type":[{"value":"2352-5568","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GFHT proposals on the practical use of argatroban \u2014 With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT)","name":"articletitle","label":"Article Title"},{"value":"Anaesthesia Critical Care & Pain Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.accpm.2021.100963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation (Sfar).","name":"copyright","label":"Copyright"}],"article-number":"100963"}}